The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children
Open accessAbstract
BACKGROUND: Oseltamivir, a specific influenza neuraminidase inhibitor, is an effective treatment for seasonal influenza. Emergence of drug-resistant influenza viruses after treatment has been reported, particularly in children in Japan, where the dosing schedule is different from that used throughout the rest of the world. We investigated the emergence of drug-resistant infection in children treated with a tiered weight-based dosing regimen. METHODS: We analyzed sequential clinical nasopharyngeal samples, obtained before and after tiered weight-based oseltamivir therapy, from children with acute influenza during 2005-2007. We isolated viruses, tested for drug resistance with use of a fluorescence-based neuraminidase inhibition assay, performed neuraminidase gene sequencing, and determined quantitative viral loads. RESULTS: Sixty-four children (34 with influenza A subtype H3N2, 11 with influenza A subtype H1N1, and 19 with influenza B virus) aged 1-12 years (median age, 3 years, 1 month) were enrolled. By days 4-7 after initiation of treatment, of 64 samples tested, 47 (73.4%) and 26 (40.6%) had virus detectable by reverse-transcriptase polymerase chain reaction and culture, respectively. By days 8-12 after initiation of treatment, of 53 samples tested, 18 (33.9%) and 1 (1.8%) had virus detectable by reverse-transcriptase polymerase chain reaction and culture, respectively. We found no statistically significant differences in the reduction of viral shedding or time to clearance of virus between viral subtypes. Antiviral-resistant viruses were recovered from 3 (27.3%) of 11 children with influenza A subtype H1N1, 1 (2.9%) of 34 children with influenza A subtype H3N2, and 0 (0%) of 19 children with influenza B virus, all of whom were treated with oseltamivir (P = .004). There was no evidence of prolonged illness in children infected with drug-resistant virus. CONCLUSIONS: Drug resistance emerges at a higher rate in influenza A subtype H1N1 virus than in influenza A subtype H3N2 or influenza B virus after tiered weight-based oseltamivir therapy. Virological surveillance for patterns of drug resistance is essential for determination of antiviral treatment strategies and for composition of pandemic preparedness stockpiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Cited by
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., McGeer, A. J., Neuzil, K. M., Pavia, A. T., Tapper, M. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598513 · Cited by 647
Drug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H., Haw, T. Y., Nutsford, A., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 439
Hayward, A. C., Fragaszy, E. B., Bermingham, A., Wang, L., Copas, A., Edmunds, W. J., Ferguson, N., Goonetilleke, N., Harvey, G., Kovar, J., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70034-7 · Cited by 407
Self-citationInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 390
Metadata
- Authors
- Stephenson, I., Democratis, J., Lackenby, A., McNally, T., Smith, J., Pareek, M., Ellis, J., Bermingham, A., Nicholson, K., & Zambon, M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02-15
- Volume
- 48
- Issue
- 4
- Pages
- 389-396
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2124505709
- Cited by
- 174
- References
- 2
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children. https://app.cochat.ai/papers/10.1086/596311
- The paper
- Stephenson, I., Democratis, J., Lackenby, A., McNally, T., Smith, J., Pareek, M., Ellis, J., Bermingham, A., Nicholson, K., & Zambon, M. (2009). Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children. Clinical Infectious Diseases. https://doi.org/10.1086/596311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.